Projects
Search from 1147 projects:
1147 Project(s)
FIDELIO
Dec 1, 2016Wirksamkeit und Sicherheit von Finerenon bei Patienten mit Typ-2-Diabetes mellitus und der klinischen Diagnose einer diabetischen Nephropathie Eine randomisierte, doppelblinde, placebokontrollierte, multizentrische, Ereignis-gesteuerte Parallelgrupp...
Clinical Studies - Dec 1, 2016 - Aug 31, 2020
Completed
Project leader: Bilz Stefan
Members: Dehos Barbara, Jenni Vera, Räss Andrea
A multicenter, randomized, 52-week, double-blind, parallel group, active controlled study to compare the efficacy and safety of QVM149 with QMF149 in patients with asthma
Nov 11, 2016Asthma is a serious global health problem affecting all age groups. Despite existing therapies, there are significant unmet medical needs in treating asthma. Novartis is developing QVM149, a fixed-dose combination (FDC) of indacaterol acetate, an inh...
Clinical Studies - Nov 11, 2016 - Mar 31, 2018
Automatically Closed
Project leader: Brutsche Martin
Members: Baty Florent, Schlotter Sandra
SAKK 24/14: Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative EGFR positive breast cancer – A multicenter single arm phase II trial
Nov 7, 2016Advanced triple negative breast cancer (TNBC) is a highly chemosensitive disease displaying a dismal short-term prognosis with more than three quarters of patients in pro-gression 12 months after the initiation of conventional chemotherapy. Approxima...
Clinical Studies - Nov 7, 2016 - May 31, 2023
Automatically Closed
Project leader: Weder Patrik
FERINJECT
Nov 1, 2016Ferric carboxymaltose is an effective parenteral therapy for iron deficiency. Because of the limited resorption and side effects of oral iron supplements parenteral iron preparations are preferred in post bariatric surgery patients to maintain normal...
Clinical Studies - Nov 1, 2016 - Jul 1, 2018
Completed
Project leader: Bilz Stefan
Members: Schöb Manuela, Räss Andrea
HIV-Proteaseinhibitoren als Basis für Krebstherapie: Verständnis des Mechanismus, Identifikation der Targets, Entwicklung wirksamerer Substanzen
Nov 1, 2016Proteasominhibitor-Resistenz ist ein wichtiger unmet clinical need beim Multiplen Myelom (MM). Die Aktivität von next generation therapy (Daratumumab, Carfilzomib, Pomalidomid) ist hier bei ca. 30 % Partialremissionen (PR). Wir haben in vitro durch...
Fundamental Research - Nov 1, 2016 - Oct 31, 2018
Automatically Closed
Project leader: Driessen Christoph
Members: Kraus Marianne, Bader Juergen, Besse Lenka, Besse Andrej
SAKK 30/15; HOVON 135: A randomized phase II multicenter study to assess the to erability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI ≥ 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged ≥ 66 years. A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFITolder AML/high-risk MDS patients
Oct 27, 2016This is a prospective, open label, multicenter study that is conducted in the frame of a masterprotocol with multiple parallel randomized phase II arms. The scheme of this design consists of one arm with the standard treatment for AML (the 10-day dec...
Clinical Studies - Oct 27, 2016 - Jul 31, 2018
Automatically Closed
Project leader: Fehr Martin
CA209-577: A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer (CheckMate 577: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 577)
Oct 21, 2016CA209577 is a phase 3, randomized, double-blind, placebo controlled study of adjuvant nivolumab in subjects with resected esophageal cancer (EC), or gastroesophageal junction (GEJ) cancer who have received chemoradiother-apy(CRT) followed by surgery....
Clinical Studies - Oct 21, 2016 - Nov 30, 2017
Automatically Closed
Project leader: Weisshaupt Christian
BIOSTEMI und BIOSTEMI Ext
Oct 12, 2016Mit dieser Studie wird die Sicherheit und Effektivität von zwei medikamentenbeschichteten Stents bei Patienten, die einen STEMI erlitten haben verglichen. Es wird geprüft, ob der Stent mit einer selbst auflösenden Beschichtung bei Patienten mit einem...
Clinical Studies - Oct 12, 2016 - Dec 30, 2023
Completed
Project leader: Weilenmann Daniel
Members: Schneider Irene
PhenoTox: Hunting the missing heritability of early-onset fluoropyrimdine-related toxicity in cancer patients: an observational multi-center study
Oct 4, 2016In cancer patients receiving fluoropyrimidine-based chemo-therapy, there is extensive inter-individual variability in plasma drug concentrations and the severity of chemo-therapy-related toxicity. A strong association has been shown for plasma concen...
Clinical Studies - Oct 4, 2016 - Feb 27, 2024
Completed
Project leader: Jörger Markus
IDN-6556-14 NASH und Emricasan
Sep 14, 2016A Multicenter, Randomized, Double-Blind, Placebo- Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Clinical Studies - Sep 14, 2016 - Sep 14, 2021
Aborted
Project leader: Semela David
Members: Alfter Christine
SASL 38 Swiss Cohort Study on Autoimmun Hepatitis
Sep 14, 2016Research project in which biological material is sampled from humans and health-related personal data is collected for research.
Clinical Studies - Sep 14, 2016 - Sep 14, 2022
Automatically Closed
Project leader: Semela David
Members: Stillhard Roman
SASL 39 Swiss Cohort Study on Primary Biliary Cholangitis
Sep 14, 2016Research project in which biological material is sampled from humans and health-related personal data is collected for research.
Clinical Studies - Sep 14, 2016 - Sep 14, 2022
Automatically Closed
Project leader: Semela David
Members: Stillhard Roman
A 52-week, multicenter, randomized, double-blind, placebocontrolled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma
Sep 11, 2016Das Ziel dieser Studie ist es, die Wirksamkeit und Sicherheit von QAW039 (150 mg und 450 mg einmal täglich) im Vergleich zu Placebo zu bestimmen, wenn es Patienten mit unzureichend kontrolliertem schweren Asthma und hoher Anzahl an Eosinophilen (Eosi...
Clinical Studies - Sep 11, 2016 - Mar 31, 2018
Automatically Closed
Project leader: Brutsche Martin
Members: Baty Florent, Schlotter Sandra
CA209451: Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy. CheckMate 451
Sep 7, 2016This is a randomized, double-blind, three-arm, multicenter, Phase 3 study in adult subjects with ED-SCLC, who achieve Stable Disease, Partial Response or Complete Response after completion of platinum based first line chemotherapy. Approximately 810...
Clinical Studies - Sep 7, 2016 - Nov 30, 2020
Automatically Closed
Project leader: Früh Martin
Monitoring of Patients’ Needs, Professional Triggers and delivered Basic Palliative Care Interventions in Routine inpatient and ambulatory of Advanced Incurable Cancer Patients: A sub-study to pilot the clinical practice tool – ESMO patient guide with KIPCC log
Sep 1, 2016Increasing evidence from randomized studies (Level A) shows that quickly integrated palliative care interventions in the treatment of cancer patients may improve the quality of life of patients and relatives, illness and prognosis understanding and s...
Clinical Studies - Sep 1, 2016 - Mar 31, 2017
Automatically Closed
Project leader: Strasser Florian
Members: Domeisen Benedetti Franzisca
REGAIN CONTROL Toujeo
Sep 1, 2016Eine 26-wöchige, randomisierte, offene, zweiarmige, pragmatische Parallelgruppenstudie unter realen Bedingungen zur Beurteilung des klinischen und gesundheitsrelevanten Nutzens des Wechsels zu Toujeo® im Vergleich zum als Therapiestandard geltenden I...
Clinical Studies - Sep 1, 2016 - Mar 14, 2018
Completed
Project leader: Aczel Stefan
Members: Räss Andrea
An open-label Phase 1/2a study of BAL101553 adminis-tered as 48-hour intravenous infusions in adult patients with advanced solid tumors
Aug 19, 2016The primary objectives of this study are to determine the maximum tolerated dose (MTD) and to characterize dose-limiting toxicities (DLTs) of BAL101553, administered as an intravenous (IV) infusion over 48 hours on study Days 1, 8 and 15 of a 28-day...
Clinical Studies - Aug 19, 2016 - Jan 31, 2018
Automatically Closed
Project leader: Jörger Markus
BI1199.214 Senscis
Aug 9, 2016A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’(SSc-ILD). A trial to compare nintedanib...
Clinical Studies - Aug 9, 2016 - Sep 8, 2017
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia, Bartz-Batliner Mira, Hutz Carina Liane, Schmidig Kathrin
Entyvio PASS Study
Jul 28, 2016Entyvio (vedolizumab) long-term safety study: An international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn’s Disease. This is a prospective, observational, multi-...
Clinical Studies - Jul 28, 2016 - Jun 28, 2022
Automatically Closed
Project leader: Brand Stephan
Members: Dora Barbara, Knellwolf Christina, Sulz Michael, Krieger-Grübel Claudia
Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy (KEYNOTE-199) / MK-3475-199 Pembro Prostata
Jul 27, 2016This is a nonrandomized, multinational, open-label trial of pembrolizumab (MK-3475) in subjects with metastatic cas-tration-resistant prostate cancer (mCRPC) previously treated with docetaxel-based chemotherapy. The trial will be conducted in conform...
Clinical Studies - Jul 27, 2016 - Jun 30, 2019
Automatically Closed
Project leader: Omlin Aurelius